Ikena Oncology, Inc. (IKNA): Price and Financial Metrics
GET POWR RATINGS... FREE!
IKNA POWR Grades
- IKNA scores best on the Value dimension, with a Value rank ahead of 81.52% of US stocks.
- IKNA's strongest trending metric is Sentiment; it's been moving down over the last 147 days.
- IKNA ranks lowest in Momentum; there it ranks in the 4th percentile.
IKNA Stock Summary
- IKENA ONCOLOGY INC's stock had its IPO on March 26, 2021, making it an older stock than only 6.81% of US equities in our set.
- Of note is the ratio of IKENA ONCOLOGY INC's sales and general administrative expense to its total operating expenses; just 11.36% of US stocks have a lower such ratio.
- As for revenue growth, note that IKNA's revenue has grown -49.59% over the past 12 months; that beats the revenue growth of merely 4.23% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to IKENA ONCOLOGY INC, a group of peers worth examining would be VTGN, HOWL, SYRS, HUMA, and MRUS.
- IKNA's SEC filings can be seen here. And to visit IKENA ONCOLOGY INC's official web site, go to ikenaoncology.com.
IKNA Valuation Summary
- IKNA's price/earnings ratio is -1.9; this is 108.19% lower than that of the median Healthcare stock.
- Over the past 24 months, IKNA's price/sales ratio has gone down 111.9.
Below are key valuation metrics over time for IKNA.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| IKNA | 2023-03-24 | 8.5 | 0.9 | -1.9 | -1.1 |
| IKNA | 2023-03-23 | 8.5 | 0.9 | -1.9 | -1.2 |
| IKNA | 2023-03-22 | 8.8 | 0.9 | -2.0 | -1.2 |
| IKNA | 2023-03-21 | 9.8 | 1.0 | -2.2 | -1.4 |
| IKNA | 2023-03-20 | 8.6 | 0.9 | -2.0 | -1.2 |
| IKNA | 2023-03-17 | 9.5 | 1.0 | -2.2 | -1.4 |
IKNA Price Target
For more insight on analysts targets of IKNA, see our IKNA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $27.00 | Average Broker Recommendation | 1.25 (Strong Buy) |
IKNA Stock Price Chart Interactive Chart >
IKNA Price/Volume Stats
| Current price | $3.60 | 52-week high | $8.30 |
| Prev. close | $3.63 | 52-week low | $1.94 |
| Day low | $3.51 | Volume | 730,700 |
| Day high | $3.89 | Avg. volume | 81,085 |
| 50-day MA | $3.99 | Dividend yield | N/A |
| 200-day MA | $3.80 | Market Cap | 130.53M |
Ikena Oncology, Inc. (IKNA) Company Bio
Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Latest IKNA News From Around the Web
Below are the latest news stories about IKENA ONCOLOGY INC that investors may wish to consider to help them evaluate IKNA as an investment opportunity.
Ikena Oncology, Inc. (IKNA) Reports Q4 Loss, Tops Revenue EstimatesIkena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of 26.42% and 67.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? |
Ikena Oncology Reports Fourth Quarter and Full Year 2022 Financial ResultsFocused targeted oncology pipeline advancing towards multiple near-term milestones; runway into 2025 Novel paralog-selective TEAD inhibitor, IK-930, advanced through multiple dose escalation cohorts, Fast Track and Orphan designations granted; initial clinical data planned for 2H 2023 Nominated potential best-in-class MEK-RAF complex inhibitor, IK-595; advancing towards IND in 2H 2023 Presented positive data from IK-175 Phase 1b clinical trial in urothelial carcinoma; Fast Track designation rece |
Ikena Oncology Presents Preclinical Data on IK-595, Best-in-Class Next-Generation MEK-RAF Complex Inhibitor, in Plenary Session at AACR Special Conference on RAS TargetingBOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that the Company is presenting preclinical data on its newest program in next-generation MEK-RAF inhibition, IK-595, at the American Association for Cancer Research (AACR) Special Conference: Targeting RAS, taking place this week in both a poster presentation and a plenary session talk. Ikena’s Chief Scien |
Ikena Oncology Receives FDA Fast Track Designation for Novel AHR Antagonist IK-175 in Combination with Nivolumab to Treat Urothelial CarcinomaBOSTON, March 06, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for IK-175, the Company’s novel aryl hydrocarbon receptor (AHR) antagonist, in combination with immune checkpoint inhibitors in patients with advanced urothelial carcinoma who have progressed on or within three months of re |
Ikena Oncology (NASDAQ:IKNA) shareholders have endured a 43% loss from investing in the stock a year agoIkena Oncology, Inc. ( NASDAQ:IKNA ) shareholders will doubtless be very grateful to see the share price up 60% in the... |
IKNA Price Returns
| 1-mo | -10.22% |
| 3-mo | 35.34% |
| 6-mo | 1.41% |
| 1-year | -41.08% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 35.34% |
| 2022 | -78.79% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...